These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 1438435
21. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E, Wang KS, Hochberg EP, Canning C, Alyea EP, Soiffer RJ, Ritz J. Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [Abstract] [Full Text] [Related]
22. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F. Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [Abstract] [Full Text] [Related]
23. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Gale RP, Horowitz MM. Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646 [Abstract] [Full Text] [Related]
24. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J. Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682 [Abstract] [Full Text] [Related]
25. [Ex-vivo treatment of a bone marrow graft]. Bieva CJ. Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193 [Abstract] [Full Text] [Related]
26. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment. Glass B, Uharek L, Gaska T, Gassmann W, Löffler H, Müller-Ruchholtz W. Bone Marrow Transplant; 1993 May; 12 Suppl 3():S41-7. PubMed ID: 8124257 [Abstract] [Full Text] [Related]
27. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia. Schots R, Van Riet I, Ben Othman T, Trullemans F, De Waele M, Van Camp B. Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544 [Abstract] [Full Text] [Related]
28. Immunomagnetic CD8 depletion. Jansen J, Hanks S, Akard L, Martin M, Ash R, Thompson J, English D. Prog Clin Biol Res; 1994 Nov; 389():551-6. PubMed ID: 7700920 [No Abstract] [Full Text] [Related]
29. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643 [Abstract] [Full Text] [Related]
30. Effect of selective donor T-cell depletion on the graft-versus-leukemia reaction in allogeneic marrow transplantation. OKunewick J, Kociban D, Machen L, Buffo M. Transplant Proc; 1992 Dec; 24(6):2998-9. PubMed ID: 1361270 [No Abstract] [Full Text] [Related]
31. Allogeneic bone marrow transplantation: state of the art and future directions. Goldman JM. Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():133-4. PubMed ID: 2653489 [Abstract] [Full Text] [Related]
32. Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation. Friedman TM, Azhipa O, Zilberberg J, Tkachuk Y, Hsu JW, Rowley SD, Goldberg SL, Korngold R, Pecora AL, Preti RA. Biol Blood Marrow Transplant; 2006 Oct; 12(10):1092-5. PubMed ID: 17084373 [No Abstract] [Full Text] [Related]
33. Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. The Study Group of Ubenimex for BMT. Hiraoka A, Shibata H, Masaoka T. Transplant Proc; 1992 Dec; 24(6):3047-8. PubMed ID: 1466051 [No Abstract] [Full Text] [Related]
35. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients. Aristei C, Aversa F, Raymondi C, Marsella AR, Panizza BM, Perrucci E, Piro F, Maranzano E, Lupattelli M, Martelli MF, Latini P. Cancer J Sci Am; 1996 Apr; 2(6):330-4. PubMed ID: 9166553 [Abstract] [Full Text] [Related]
36. Reconstitution of the CD45RO(+) and CD20(+) lymphoid marrow population following allogeneic bone marrow transplantation for Ph(+) CML. Thiele J, Kvasnicka HM, Beelen DW, Welter A, Schneider S, Leder LD, Schaefer UW. Bone Marrow Transplant; 2001 Feb; 27(4):425-31. PubMed ID: 11313672 [Abstract] [Full Text] [Related]
37. The clinical use of elutriation and positive stem cell selection columns to engineer the lymphocyte and stem cell composition of the allograft. Noga SJ, Davis J, Schepers K, Eby L, Berenson RJ. Prog Clin Biol Res; 1994 Feb; 389():317-24. PubMed ID: 7535437 [No Abstract] [Full Text] [Related]
38. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation. Yabe M, Yabe H, Hattori K, Hinohara T, Morimoto T, Kato S, Kusunoki A. Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006 [Abstract] [Full Text] [Related]
39. Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors. Goldman JM, Mackinnon S. Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():38-9. PubMed ID: 2627622 [Abstract] [Full Text] [Related]
40. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R. Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]